EVEROLIMUS | A218488 | APOTEX INC
No patent or exclusivity listings for this strength.
Apotex's abbreviated new drug application for everolimus (ANDA 218488, supplement 002) received FDA approval.
New: New record
Apotex received FDA approval for Everolimus (NDA 218488, Supplement 003).
New: New record
Apotex received FDA approval for a new everolimus product (NDA 218488, Supplement 004).
New: New record
Apotex's everolimus product (NDA 218488, strength 001) was added to the FDA product database.
New: New record